Published 26th September 2024
Successfully applying for and maintaining orphan designation in the European Union (EU) is a critical pathway for sponsors developing treatments for rare diseases. The process involves navigating regulatory frameworks set by the European Medicines Agency (EMA) under Regulation (EC) No 141/2000.
Once granted, maintaining this status requires ongoing compliance with regulatory obligations, including regular reporting on the development status, marketing exclusivity updates, and adherence to timelines.
In this whitepaper we provide key reflections for navigating potential challenges in the preparation of an orphan designation application, such as classification of the orphan condition, prevalence estimation, evidence of significant benefit, and medical plausibility. We emphasise the importance of a pre‑submission meeting for obtaining an orphan designation, and about generating evidence during the marketing authorisation (MA) process to maintain the designation. We also review the benefits and incentives of orphan designations such as protocol assistance, market exclusivity, access to EU grants, and fee reductions, which are vital for the commercial viability of orphan drugs in the EU. Finally, we highlight how the new EU pharmaceutical reforms are going to impact orphan designations.
Need personalised assistance to guide you through the regulatory process to bring your products to market? Contact our experts at hello@dlrcgroup.com
Download nowPublished Oct 21, 2024
Published Oct 18, 2024
Published Oct 10, 2024
Published Oct 07, 2024
Published Sep 26, 2024
Published Sep 24, 2024
Published Sep 10, 2024
Published Aug 30, 2024
Published Aug 19, 2024